Photo by ldxcreative from unsplash
Atezolizumab plus bevacizumab (Atez/Bev) therapy is expected to have good therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However, the clinical indicators that predict therapeutic efficacy have not been… Click to show full abstract
Atezolizumab plus bevacizumab (Atez/Bev) therapy is expected to have good therapeutic efficacy for patients with advanced hepatocellular carcinoma (HCC). However, the clinical indicators that predict therapeutic efficacy have not been established. We retrospectively investigated whether the neutrophil‐to‐lymphocyte ratio (NLR) during Atez/Bev therapy could predict therapeutic efficacy.
Keywords:
efficacy patients;
therapy;
efficacy;
atezolizumab plus;
therapeutic efficacy;
plus bevacizumab
Journal Title: Hepatology Research
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!